BioWorld

July 26, 2007

View Archived Issues

Merck Paying $350M In Stock For Acquisition Of NovaCardia

NovaCardia Inc., which has a Phase III product for congestive heart failure, is being acquired by Merck & Co. Inc. for $350 million in stock. (BioWorld Today) Read More

Amid Fallout From Panel Vote, Spectrum Signs License Deal

Read More

Cell Therapeutics Gets Phase II Cancer Drug In SMi Acquisition

Read More

Imarx Goes Public With $15M Offering; Archemix Files For IPO

Read More

Genzyme Beats Q2 Estimates On Higher Than Expected Revenue

Read More

Other News To Note

Read More

AIDS Clinic Roundup

Read More

Clinic Roundup

Read More